Public Company

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is a clinical stage neuroscience company developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders.


Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics targeting age-related degenerative diseases and disorders specific to the central nervous system, or CNS, and retina with a goal to develop treatments that can modify the diseases in patients with these disorders. The company has expert experience in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses. It also acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina.


Founded 2007
Type Public
Longevity related Yes
Location Pennsylvania, USA Purchase, Harrison, New York, USA

Recent Jobs at Cognition Therapeutics, Inc.

Latest News


CGTX $2.08 7.27% $0.14